The Effect of Low Dose Hormone Replacement Therapy or Raloxifene on Bone and Lipid Metabolism in Hemodialysis Patients
Not Applicable
- Conditions
- Postmenopausal osteopenia in hemodialysis patients
- Registration Number
- JPRN-C000000390
- Lead Sponsor
- Department of Nephrology, Osaka University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 39
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with arteriosclerosis obliterans 2. Patients at high risk of venous thrombosis. i.e. bedridden patients 3. Patients with history of uterine cancer and/or breast cancer. 4. Patients receiving specific treatments other than active vitamin D that affect bone and mineral metabolism. i.e. calcitonin, bisphosphonate, and recombinant human PTH.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in serum calcium, phosphorus, parathyroid hormone, bone markers and lipid metabolism
- Secondary Outcome Measures
Name Time Method Change in bone mineral density at the radius on the side without atrio-venous fistula